Press releases

Regulatory

December 17, 2018

Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting

Regulatory

December 14, 2018

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

Regulatory

November 30, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

November 30, 2018

Oasmia Pharmaceutical AB (publ)

Regulatory

November 29, 2018

Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®

Regulatory

November 28, 2018

Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company’s warrants 2018/2019

Regulatory

November 22, 2018

Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union

Regulatory

November 20, 2018

New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR-17 has been granted

Regulatory

November 1, 2018

Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million

Non Regulatory

October 31, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

October 3, 2018

Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma

Regulatory

September 30, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

September 25, 2018

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018

Regulatory

September 21, 2018

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

Regulatory

September 18, 2018

Update regarding the Market Authorization Application of Apealea in the European Union

Regulatory

September 7, 2018

Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million

Non Regulatory

August 31, 2018

Oasmia Pharmaceutical AB (publ)

Non Regulatory

August 30, 2018

Notification from Oasmia Pharmaceutical AB

Regulatory

August 24, 2018

Oasmia Pharmaceutical publishes the Annual Report for 2017/2018

Non Regulatory

August 24, 2018

NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB

Non Regulatory

August 1, 2018

Notification from Oasmia Pharmaceutical AB

Regulatory

July 31, 2018

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

July 27, 2018

Status of the Market Authorisation Application of Apealea in the European Union

Regulatory

July 27, 2018

Status of Orphan designation of Apealea in the European Union

Regulatory

June 8, 2018

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

Regulatory

June 5, 2018

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

Regulatory

May 30, 2018

Nexttobe Extends Loan to Oasmia Pharmaceutical

Regulatory

May 21, 2018

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

Regulatory

May 17, 2018

Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

Non Regulatory

May 16, 2018

Notification from Oasmia Pharmaceutical

Non Regulatory

May 8, 2018

Notification from Oasmia Pharmaceutical AB

Non Regulatory

May 2, 2018

Notification from Oasmia Pharmaceutical AB

Non Regulatory

April 24, 2018

Notification from Oasmia Pharmaceutical AB

Regulatory

April 19, 2018

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

Non Regulatory

March 2, 2018

Oasmia Pharmaceutical AB (publ)

Regulatory

February 19, 2018

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Regulatory

January 24, 2018

Directed issue of warrants in Oasmia Pharmaceutical AB

Regulatory

January 2, 2018

Oasmia Pharmaceutical Secures Financing of 108 MSEK